Last updated: November 13, 2026
JNJ-53718678, also known as sisunatovir, is an oral respiratory syncytial virus (RSV) fusion inhibitor developed by Janssen Pharmaceuticals. Its clinical program did not establish efficacy in hospitalized pediatric RSV patients, and public development records indicate that the program was terminated. JNJ-53718678 has no FDA approval, no commercial sales, no Orange Book listing, and no current branded market.
The base-case commercial projection is therefore $0. Any future value would depend on a new sponsor restarting development with a different target population, endpoint strategy, or treatment setting.
What is the current development status of JNJ-53718678?
JNJ-53718678 is no longer an active late-stage development asset based on its public clinical-trial record.
| Field |
Status |
| Active ingredient |
Sisunatovir |
| Development code |
JNJ-53718678 |
| Sponsor |
Janssen Research & Development, LLC |
| Mechanism |
Small-molecule RSV fusion inhibitor |
| Route |
Oral |
| Primary target |
RSV infection, including lower respiratory tract disease |
| Highest publicly documented stage |
Phase 2b |
| FDA approval |
None |
| Commercial launch |
None |
| Orange Book listing |
None |
| Current revenue |
$0 |
| Public development status |
Terminated or discontinued |
The key development effort involved hospitalized infants with RSV lower respiratory tract infection. The program was designed to test whether early antiviral treatment could improve clinical outcomes and reduce viral burden. The available record does not support progression into Phase 3 registration studies.
What clinical trials evaluated JNJ-53718678?
Janssen evaluated JNJ-53718678 in several RSV populations, including adults and children. The most commercially relevant program focused on hospitalized infants, where the unmet need for a direct-acting RSV treatment remains high.
Key clinical development areas
| Population |
Development objective |
Outcome |
| Healthy adults |
Safety, pharmacokinetics, antiviral activity |
Early clinical development |
| Adults with RSV infection |
Viral and clinical response |
No registration pathway established |
| Hospitalized infants |
Treatment of RSV lower respiratory tract infection |
Program did not advance to Phase 3 |
| Pediatric patients |
Dose selection and proof of concept |
Development discontinued |
The pediatric program was important because infants hospitalized with RSV represent a concentrated, high-cost treatment population. The clinical challenge was substantial: many hospitalized infants improve with supportive care, making it difficult for an antiviral to demonstrate a statistically and clinically meaningful reduction in hospitalization duration or respiratory support.
ClinicalTrials.gov records identify studies of JNJ-53718678 in RSV-infected patients, including pediatric hospitalized populations. The records show that the program did not progress into an approval-enabling development plan.[1]
Why was JNJ-53718678 discontinued?
The principal issue was insufficient clinical efficacy rather than a lack of biological rationale.
Sisunatovir inhibits the RSV fusion protein, a validated antiviral target. The mechanism is designed to prevent viral entry and cell-to-cell spread. The program nevertheless faced several development risks:
- Treatment often began after substantial RSV replication had occurred.
- Hospitalized infants have heterogeneous disease severity and variable natural recovery.
- Clinical outcomes such as oxygen use and length of stay are influenced by supportive-care practices.
- Viral-load reductions may not translate into shorter hospitalization or improved respiratory outcomes.
- RSV disease differs materially by age, viral subtype, prior immunity, and comorbidities.
Publicly available development records do not show a transition to Phase 3 after the pediatric proof-of-concept work. Janssen’s subsequent pipeline disclosures also do not identify sisunatovir as an active commercial-stage program.[2]
What is the market opportunity for an RSV antiviral?
The theoretical market opportunity is meaningful, but JNJ-53718678 has no current share of it.
RSV treatment and prevention markets are divided into four segments:
| Segment |
Principal products or approaches |
Relevance to JNJ-53718678 |
| Infant prevention |
Nirsevimab and palivizumab |
Competitive substitute, not direct treatment |
| Maternal immunization |
RSVpreF vaccination |
Reduces infant infection risk |
| Adult prevention |
RSV vaccines for older adults |
Limits treatable disease burden |
| Acute treatment |
Supportive care and limited antiviral use |
Intended market for sisunatovir |
Nirsevimab, marketed as Beyfortus by AstraZeneca and Sanofi, has materially changed the infant RSV prevention market. Abrysvo and Arexvy have expanded prevention options in adult and maternal populations. These products reduce the number of severe RSV cases that could otherwise become candidates for inpatient antiviral treatment.
The remaining treatment opportunity is concentrated in:
- Infants hospitalized despite prophylaxis or maternal immunization.
- Young children with severe lower respiratory tract disease.
- High-risk adults, including older patients and immunocompromised individuals.
- Earlier outpatient treatment before progression to hospitalization.
A successful oral RSV antiviral could command value through reduced hospitalization costs, shorter oxygen use, and lower intensive-care utilization. JNJ-53718678 did not demonstrate a sufficient clinical profile to capture that opportunity.
What is the five-year market projection for JNJ-53718678?
The base-case forecast is zero revenue because the asset has not been approved and its clinical program has been discontinued.
| Projection scenario |
Probability profile |
Commercial outcome |
| Base case |
No restart or partnering activity |
$0 revenue |
| Restart case |
New clinical program in a better-defined population |
No revenue before new clinical validation and approval |
| Successful redevelopment case |
Positive Phase 2 and Phase 3 data followed by approval |
Potential niche RSV-treatment product |
| Broad commercial case |
Demonstrated benefit in hospitalized and outpatient patients |
Larger addressable market, but unsupported by current data |
A commercial forecast based on the historical clinical program would overstate the asset’s value. There is no approved indication, launch date, price, reimbursement status, or current prescriber base on which to build a conventional revenue model.
A redevelopment scenario would require a new investment cycle:
- Reconfirm the molecule’s clinical and regulatory viability.
- Select a treatment population with measurable outcomes.
- Establish dose and exposure requirements in infected patients.
- Demonstrate an antiviral and clinical benefit.
- Conduct a registration-quality Phase 3 trial.
- Secure FDA approval and commercial rights.
Even if the molecule retained patent life, patent rights would not compensate for the absence of clinical proof and regulatory approval.
What is the competitive landscape for JNJ-53718678?
Sisunatovir competed in a field that has become more differentiated since its initial development.
Direct antiviral competitors
The primary direct-acting RSV competitor is presatovir, also known as GS-5806, developed by Gilead Sciences. Presatovir also encountered efficacy challenges in clinical development, particularly in hospitalized adults. The experience of both molecules indicates that RSV antiviral development requires early treatment and carefully selected endpoints.
Other investigational RSV fusion inhibitors and polymerase inhibitors have pursued outpatient or high-risk populations. The strongest development strategies have generally focused on:
- Early diagnosis.
- Treatment before extensive lower-airway damage.
- High-risk patients with a predictable disease course.
- Quantifiable reductions in viral load and clinical deterioration.
- Combination treatment to reduce resistance risk.
Preventive competitors
Prevention has become the main commercial segment in RSV:
- Beyfortus, nirsevimab, is a long-acting monoclonal antibody for infant protection.
- Synagis, palivizumab, remains available for selected high-risk infants.
- Abrysvo is approved for specified maternal and adult populations.
- Arexvy is approved for older adults.
These products do not eliminate the need for treatment, but they reduce the potential patient pool for a hospitalized-infant antiviral.
What is the FDA regulatory status of JNJ-53718678?
JNJ-53718678 is not FDA approved.
The asset has:
- No approved label.
- No New Drug Application approval.
- No FDA-recognized commercial indication.
- No FDA exclusivity period.
- No established pediatric approval.
- No approved dosing regimen.
- No Orange Book listing.
Because the product was never approved, it has no regulatory exclusivity timeline comparable to a marketed small-molecule drug. A future sponsor would likely need to submit a new regulatory package, although prior clinical and nonclinical data could potentially support discussions with the FDA.
What patents protect JNJ-53718678?
No FDA-listed patents protect JNJ-53718678 because the product has no approved reference drug and does not appear in the Orange Book.
The underlying molecule, formulations, salts, manufacturing processes, and therapeutic uses may have been covered by Janssen or related patent families. Those rights are separate from FDA-listed patents and may include:
- Composition-of-matter claims.
- RSV treatment claims.
- Pediatric dosing claims.
- Oral formulation claims.
- Solid-state or salt-form claims.
- Synthetic intermediates and manufacturing processes.
A definitive patent-expiration analysis cannot be inferred from the development code alone. The commercial significance of any remaining patent term would also depend on claim scope, terminal disclaimers, prosecution history, validity, and freedom-to-operate issues.
Formulation and manufacturing barriers
Sisunatovir was developed as an oral small molecule, which generally creates fewer manufacturing barriers than an injectable biologic or monoclonal antibody. The principal technical risks would involve:
- Stable oral exposure across infants and adults.
- Pediatric liquid or dispersible dosage forms.
- Food-effect management.
- Dose scaling in premature or low-weight infants.
- Resistance-associated substitutions in the RSV fusion protein.
- Consistent commercial-scale synthesis.
These issues are manageable in principle but would require renewed development work if the program were restarted.
Are there Paragraph IV challenges or patent litigation involving JNJ-53718678?
No meaningful Paragraph IV litigation is expected because JNJ-53718678 has not reached FDA approval and has no Orange Book-listed reference product.
Publicly documented records do not identify a generic challenger, ANDA litigation, Hatch-Waxman settlement, or commercial patent dispute involving sisunatovir. Generic entry is therefore not the current risk. The primary risk is clinical and regulatory failure.
If the molecule were redeveloped and approved, later generic exposure would depend on:
- Remaining composition-of-matter patent term.
- Validity and scope of formulation claims.
- Method-of-use claims.
- Pediatric exclusivity.
- Any granted patent-term extension.
- FDA approval timing.
Which companies could challenge or replace JNJ-53718678?
The competitive threat comes from approved prevention products and alternative RSV antivirals rather than generic manufacturers.
| Company |
Asset or product |
Competitive effect |
| AstraZeneca and Sanofi |
Nirsevimab, Beyfortus |
Reduces infant RSV incidence and hospitalization |
| AstraZeneca |
Palivizumab, Synagis |
Existing high-risk infant prevention |
| Pfizer |
RSVpreF, Abrysvo |
Maternal and adult prevention |
| GSK |
Arexvy |
Older-adult prevention |
| Gilead Sciences |
Presatovir and other RSV programs |
Direct antiviral competition |
| Other biotechnology companies |
Fusion and polymerase inhibitors |
Potential future treatment competition |
For a restarted sisunatovir program, the most attractive differentiation would likely be oral dosing, early outpatient use, and activity in a high-risk population not adequately protected by prophylaxis.
How strong is the commercial outlook for JNJ-53718678?
The current commercial outlook is weak.
The asset has positive attributes:
- Oral small-molecule administration.
- A biologically credible RSV fusion mechanism.
- Potential application across pediatric and adult populations.
- A treatment area with substantial medical need.
The asset also has decisive weaknesses:
- No approval.
- No current clinical development program.
- No demonstrated registration-level efficacy.
- No commercial manufacturing or distribution infrastructure.
- Competition from effective preventive products.
- Difficult RSV clinical endpoints.
- No established reimbursement value.
On balance, JNJ-53718678 should be valued as a discontinued clinical asset rather than as a near-term product opportunity. Any transaction value would be based on discounted option value, salvageable intellectual property, and the cost of restarting development, not on projected near-term product revenue.
Key Takeaways
- JNJ-53718678, or sisunatovir, is an oral RSV fusion inhibitor developed by Janssen.
- The program reached Phase 2b but did not advance to Phase 3.
- Public development records indicate discontinuation, particularly after pediatric hospitalized-patient development.
- The drug has no FDA approval, Orange Book listing, regulatory exclusivity, or commercial revenue.
- The base-case five-year revenue projection is $0.
- The theoretical RSV treatment market remains attractive, but approved prevention products reduce the addressable infant population.
- No Paragraph IV challenges, generic litigation, or settlement agreements are associated with the unapproved asset.
- Any future value would require a new sponsor, a revised clinical strategy, and fresh proof of efficacy.
FAQs About JNJ-53718678
Is JNJ-53718678 the same drug as sisunatovir?
Yes. Sisunatovir is the generic name associated with the development code JNJ-53718678.
Can JNJ-53718678 still be approved?
Approval is theoretically possible only through renewed development and successful clinical trials. The public record does not show an active registration program.
Does JNJ-53718678 compete with Beyfortus?
Indirectly. Beyfortus prevents RSV disease in infants, while sisunatovir was intended to treat established infection. Broader use of Beyfortus would reduce the number of infants available for treatment with a future RSV antiviral.
Is JNJ-53718678 available through expanded access?
There is no established commercial or routine expanded-access pathway identified for sisunatovir.
What is the investment case for JNJ-53718678?
The investment case is limited to option value from the molecule, related intellectual property, or a potential redevelopment program. There is no current product revenue or near-term launch opportunity.
References
-
ClinicalTrials.gov. (n.d.). Studies of JNJ-53718678 in participants with respiratory syncytial virus infection. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Johnson & Johnson. (2021). Annual report for fiscal year 2021. https://www.jnj.com/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2023). FDA approves first vaccine for pregnant individuals to prevent RSV in infants. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2023). FDA approves new drug to prevent RSV in infants and young children. https://www.fda.gov/